Drugs / anti-EGFR CAR T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02331693 | Dec 2014 → Dec 2015 | malignant glioma | RenJi Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-EGFR CAR T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02331693 ↗ |
| Modality | Cell therapy | “ex vivo tumor reactive, CAR gene-transduced T cells” NCT02331693 ↗ |
| Route | Intravenous | “intravenous infusion of ex vivo tumor reactive, CAR gene-transduced T cells” NCT02331693 ↗ |
| Target | EGFR | “CAR that recognizes overexpressed EGFR in tumor cells” NCT02331693 ↗ |